Pfizer's Sutent improves survival without surgery in RCC patients

Data from the Phase III CARMENA trial evaluating Sutent sunitinib from Pfizer Inc. (NYSE:PFE) showed that patients with renal cell carcinoma (RCC) could avoid nephrectomy without compromising survival. The data were presented at the American Society of Clinical Oncology (ASCO)

Read the full 400 word article

User Sign In